Abstract: There is now described a method of controlling pests with pymetrozine, profenofos, a benzoylurea-derivative or a carbamat-derivative; more specifically a method of controlling pests in and on transgenic crops of useful plants, such as, for example, in crops of maize, cereals, soya beans, tomatoes, cotton, potatoes, rice and mustard, with pymetrozine, profenofos, a benzoylurea-derivative, especially lufenuron; or a carbamat-derivative, especially fenoxycarb; characterized in that a pesticidal composition comprising pymetrozine, profenofos, a benzoylurea-derivative or a carbamat-derivative, in free form or in agrochemically useful salt form and at least one auxiliary is applied to the pests or their environment, in particular to the crop plant itself.

Abstract: There is described a method of treatment of a patient requiring analgesia which comprises the separate, simultaneous or sequential administration of a therapeutically effective amount of an opioid analgesic, devazepide and a surfactant.

Abstract: This invention provides the use of CCI-779 in the treatment of neoplasms.

Abstract: The present invention relates to the use of a compound of formula (I): 1

Abstract: The invention provides compounds of Formula I: 1

Abstract: The present invention relates to novel thiourca derivatives as a modulator for vanilloid receptor (VR) and the phar- maceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflam- matory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

Abstract: The invention provides novel &bgr;2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with &bgr;2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.

Abstract: The invention provides methods for treating Parkinson's disease by administering a therapeutically effective amount of at least one cholinesterase inhibitor compound, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. A preferred cholinesterase inhibitor compound is donepezil, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof.

Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

Abstract: This invention encompasses the Form V polymorph of Compound A of structural formula: 1

Abstract: The present invention relates to certain substituted polyketides of formula I, 1

Abstract: A class of 3,4-diaryl substituted thiophene, furan and pyrrole derivatives and analogs thereof, pharmaceutical compositions containing them and methods of using them to treat inflammation and inflammation-related disorders.

Abstract: An agent for enhancing accumulation of drugs in tumor tissues, which can enhance accumulation of the drugs in tumor tissues, which drugs are used for diagnosis or therapy of tumors, is disclosed. The agent for enhancing accumulation of drugs in tumor tissues according to the invention comprises as an effective ingredient a prostaglandin I derivative such as beraprost or a salt thereof.

Abstract: This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Abstract: The present invention relates to the use of 2-amino-4-pyridylmethyl thiazoline derivatives of formula (I) 1

Abstract: The present invention relates to certain substituted heterocycles of Formula (I) which are useful in the treatment of diseases related to lipid and carbohydrate metabolism, such as type 2 diabetes, adipocyte differentiation, uncontrolled proliferation, such as lymphoma, Hodgkin's Disease, leukemia, breast cancer, prostate cancer or cancers in general; and inflammation, such as osteoarthritis, rheumatoid arthritis, Crohn's Disease or Inflammatory Bowel Disease.

Abstract: A pharmaceutical composition which composition comprises an insulin sensitiser and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of the insulin sensitiser and the use of such composition in medicine.

Abstract: Stable pharmaceutical preparations, comprising torasemide in noncrystalline form.

Abstract: The present invention is directed C2-disubstituted indan-1-ones of the Formula I, 1

Abstract: The invention relates to the field of blood coagulation.

Abstract: 1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.

Abstract: The present invention provides a method of treating Restless Legs Syndrome in human or animal patient, which method comprises administering to said patient an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof. Preferably, a dose of ropinirole or a pharmaceutically acceptable salt or solvate thereof is administered to the patient 1 to 3 hours before the patient goes to bed. A typical dose comprises 0.1 mg -5 mg of ropinirole. The invention also provides a pharmaceutical composition for use in the treatment of Restless Legs Syndrome which comprises an effective amount of ropinirole or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.

Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

Abstract: A method is provided for preparing a pharmaceutical composition comprising: taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen for a period of time, the exposure to the gas over the period of time causing an acidity of the polyoxyethylated castor oil to increase; and forming a pharmaceutical composition comprising the aged polyoxyethylated castor oil and a pharmaceutically active agent such as paclitaxel; wherein at least 80% of the potency of the pharmaceutically active agent is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40° C.

Abstract: Dictyostatin-1 has been found to stabilize microtubules and prohibit their depolymerization to free tubulin. Because of these activities, the dictyostatin compounds can be used in the treatment of a number of diseases in which aberrant cellular proliferation occurs such as drug-sensitive and drug-resistant cancers, autoimmune disorders, and inflammatory diseases.

Abstract: A process for separation of specific tocopherols from a mixture of tocopherols is disclosed. The process includes methods of separation of the tocopherols from residues of vegetable oil refining and other various food sources by dissolving in organic solvents and eluting over non-ionic adsorbent resins.

Abstract: A pharmaceutical tablet comprising an effective amount of simvastatin provides several advantages including reliable or improved storage stability by having a pH within the range of 5.0 to 7.5, based on a 20 wt % aqueous slurry.

Abstract: We have discovered that the topical application of the amino acid lysine and the 6-methyl derivative of lysine to Herpes simplex virus Type II is therapeutically beneficial and relieves the discomfort and symptoms of HSV infections and prevents or reduces the number of severity of HSV infections. We have also discovered that derivatives of lysine, in addition to 6-methyl lysine and derivatives of arginine have an inhibitory effect upon HSV replication. These compounds are useful in the prevention and treatment of HSV lesions.

Abstract: Mammalian hair growth can be reduced by topical application of an inhibitor of fatty acid metabolism.

Abstract: The treatment of humans or other mammals for eczema and/or psoriasis using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate.

Abstract: This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperplasia and restoring vessel wall biocompatibility.

Abstract: An ophthalmic solution or contact lens solution comprising at least one germicidal/preservative component. The ophthalmic solution further comprises at least one selected amino-acid-based component, 0-0.2 wt. % of sodium chloride, and 0-0.5 wt. % of phosphate. The contact lens solution further comprises at least one selected acidic component and 0-0.2 wt. % of sodium chloride. Alternatively, the contact lens solution further comprises at least one selected amino-acid-based component, at least one selected acidic compound, and 0-0.2 wt. % of sodium chloride.

Abstract: A readily absorbable solid composition comprising sparingly soluble NSAIDs of the propionic acid type, a water-soluble polymeric base, and a nonionic surfactant.

Abstract: The present invention provides novel compositions and methods for using the S(+) enantiomer of desmethylselegiline (N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane), for the treatment of selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.

Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein.

Abstract: A method for decreasing intraocular pressure by administering an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen. These agents, by inhibiting influx or promoting efflux of aqueous humor, can be used to treat glaucoma.

Abstract: Compounds used to block non-essential androgen receptors are described. In particular, cyclohexenone compounds containing an alkyl group may be used in the treatment of conditions mediated by the blocking of non-essential androgen receptors such as acne, male patterned baldness, keloids, skin-wrinkling, and osteoarthritis. The cyclohexenone compound may be administered orally, topically, or internally.

Abstract: 1

Abstract: Methods and compositions for inhibiting the production of exotoxins are disclosed.

Abstract: A method for preparing dispersions of solid salts of fatty acids in low polarity liquids where a concentrated mixture of at least 50 percent of the solid salts of fatty acids in a low polarity liquid is subjected to high shearing forces, until the average particle size of the solid salts of fatty acids is less than 3 micron. The dispersion may then be diluted with the low polarity liquid to a lower concentration. The solid salt of the fatty acid is most preferably magnesium stearate, and the low polarity liquid is preferably a polydimethylsiloxane fluid having a viscosity of less than 100 centistoke (mm2/s).

Abstract: The present invention pertains to a method for controlling the foaming of a waterborne composition or in an industrial process utilizing a waterborne composition by the incorporation of a foam controlling agent in an amount effective for controlling foam.

Abstract: The present invention is an improvement in the preparation of liquid hydrocarbons from natural gas/methane, oxygen and/or steam. In particular, the present invention relates to processes for the production of synthesis gas, reducing the oxygen concentration from the synthesis gas, and the production of liquid hydrocarbons using the oxygen reduced synthesis gas as a feedstock. More particularly, the present invention described herein identifies catalyst compositions, apparatus and methods of using such catalysts and apparatus for preparing liquid hydrocarbons via oxygen reduced synthesis gas all in accordance with the present invention.

Abstract: The invention provides a process for the production or mainly C5+ hydrocarbons comprising contacting carbon monoxide and hydrogen at a temperature in the range of from 180 to 270° C. and elevated pressure in the presence of a catalyst composition comprising cobalt, manganese and at least one of rhenium and/or ruthenium on a titania carrier; a catalyst composition comprising cobalt, manganese and rhenium on a titania carrier.

Abstract: Methods for producing a substantially paraffinic Fischer-Tropsch product or a blended Fischer Tropsch product comprising a selected oxygenate concentration, and if required, a selected oxygenate concentration of specific individual oxygenates, are disclosed. The methods of the present invention measure oxygenate concentration using GC-AED. The oxygenate measurements obtained using the GC-AED may be used to adjust and control various processes used to produce, upgrade, or finish Fischer Tropsch products to provide Fischer Tropsch products with a selected oxygenate concentration, and if required, a selected oxygenate concentration of specific individual oxygenates.

Abstract: The present invention relates to a process for the production of a cellular composite, and to the resultant cellular composites. This process comprising (A) preparing a mixture of a polyisocyanate, water, and, optionally, one or more additives; (B) adding this mixture under low shear mixing to inorganic hollow microspheres; (C) completely filling a mold with the mixture; and (D) heating the mold containing the mixture to a temperature of from 100 to 280° C., thereby forming the composite.

Abstract: A mesoporous polymer and method of preparing a mesoporous polymer whose polymerization kinetics are dependent upon pH and whose pore size is controlled by pH and solvent concentration are disclosed. The polymer is optionally pyrolyzed to form a primarily carbonaceous solid. The material has an average pore size in the mesopore range and is suitable for use in liquid-phase surface limited applications including chromatographic, sorbent, catalytic, and electrical applications.

Abstract: A method for producing a porous cross-linked polymer sheet capable of slicing quickly is provided. This method comprises a step for obtaining a porous cross-linked polymer by forming and polymerizing an HIPE, a step for dehydrating the porous cross-linked polymer, and a step for subsequently slicing the dehydrated porous cross-linked polymer. According to this invention, by performing the step of dehydration prior to the conventional step of slicing, it is made possible to prevent the porous cross-linked polymer from adhering to the blade and the guides provided for a slicer, and allow the slicing to be attained quickly. By removing the salt from the polymer, it is further made possible to prevent a production device from gathering rust and the porous cross-linked polymer from permitting adhesion of rust thereto.

Abstract: The present invention relates to crosslinking of porous materials made of biodegradable polymers. The method comprises: (a) placing a porous biodegradable polymer in a chamber; (b) introducing a supercritical fluid containing a crosslinking agent into the chamber to effect crosslinking of the porous biodegradable polymer; and optionally (c) introducing a pure supercritical into the chamber to wash the crosslinked polymer until the crosslinking agent is substantially removed from the polymer.

Abstract: An ester polyurethane foam is prepared by reacting a mixture of one or more polyester polyols with one or more isocyanates and one or more silicone surfactants in the presence of a blowing agent, such as water, and other additives, such as catalysts. The cured foam is chemically treated in a caustic solution to form a hydrophilic ester polyurethane foam having a water absorption rate of at least 20 pounds of water per square foot per minute, preferably at least 25 pounds of water per square foot per minute. The foam also has greater water holding capacity and wet strength than cellulose.

Abstract: The present invention relates to powdered thermosetting compositions including a binder which comprises a carboxyl group containing amorphous isophthalic acid containing polyester, a carboxyl group containing semi-crystalline polyester, at least 10 parts by weight, based on the total weight of the binder, of a specific glycidyl group containing acrylic copolymer and a curing agent having functional groups reactive with the polyesters' carboxyl groups. The powdered thermosetting compositions are useful for the preparation of powdered paints and varnishes which give low gloss coatings having an outstanding flow, a remarkable weatherability and excellent mechanical properties.